Integration of “omics” and potential for clinical practice

“Omics” have accelerated drug discovery for clinical practice and are therefore promising elements in optimising IBD treatment [22]. They can be used for each of the four basic components in IBD pathogenesis (see Table).

Table: Basic components of IBD and their treatment strategies [24]



Omics-based biomarkers for clinical practice are able to detect subtypes (molecular signatures). Thus, they suit a holistic view of the patient integrating the person, the affected organ, its lesion, as well as cell and molecular structures [23,34].